For those who are worried about the end of 2026 for recruiting...

For those who are worried about the end of 2026 for recruiting timeline.

Hey chatGPT are there any examples of oncology drugs that have been bought out straight after preliminary data in a open label phase 1 clinical trial has been released?

ChatGPT: Yes, there are several examples of oncology drugs that have been acquired after promising preliminary data from open-label Phase 1 clinical trials. Pharmaceutical companies often seek to acquire innovative cancer therapies early in their development based on encouraging early-stage data. Here are a few notable examples:

Loxo Oncology and Bayer:
Drug: LOXO-292 (later named selpercatinib)
Acquisition: Loxo Oncology was acquired by Eli Lilly for approximately $8 billion in 2019, following promising early clinical data, including Phase 1 results.
Details: LOXO-292 showed promising activity against RET fusion-positive cancers in Phase 1 trials, attracting significant interest and leading to the acquisition.

Juno Therapeutics and Celgene:
Drug: JCAR017 (later named lisocabtagene maraleucel or liso-cel)
Acquisition: Celgene acquired Juno Therapeutics for $9 billion in 2018.
Details: The acquisition was driven by positive early-stage data from open-label trials showing the efficacy of JCAR017, a CAR T-cell therapy, in treating B-cell malignancies.

ArQule and Merck:
Drug: ARQ 531
Acquisition: Merck acquired ArQule for $2.7 billion in 2019.
Details: ARQ 531, a BTK inhibitor, showed promising results in Phase 1 trials for treating B-cell malignancies, prompting Merck to make the acquisition.

Immunomedics and Gilead Sciences:
Drug: Sacituzumab govitecan (Trodelvy)Acquisition: Gilead Sciences acquired Immunomedics for $21 billion in 2020.
Details: Early Phase 1/2 data showed significant efficacy in triple-negative breast cancer, leading to the acquisition.

These acquisitions illustrate the high value placed on early promising data in the oncology field and the strategic importance of acquiring innovative therapies to strengthen pharmaceutical companies' oncology portfolios.

I have not checked the details, apparently AI can hallucinate, but the response is encouraging nonetheless.